Monitoring oxidative stress biomarkers in the lipidome: Is there a roadmap for "Human inspection"?

Jungnickel,H.; Tentschert,J.; Luch,A.

doi:10.2174/156652412800792606

referiert

Veröffentlicht

Monitoring oxidative stress biomarkers in the lipidome: Is there a roadmap for "Human inspection"?

Oxidative stress is more and more recognized as the underlying motif for a broad variety of diseases including cancer. Medicine faces the paramount task to develop better diagnostic tools and drug treatment prediction models in the future to significantly enhance the quality of life. Special interest will focus on earlystage disease biomarkers and biomarkers that could predict healing success at the earliest time point after the treatment started. The accelerated formation of so-called reactive oxygen species (ROS) is becoming widely regarded as the underlying process associated with many diseases like myocardial infarction, Alzheimer's, Parkinson's and kidney disease, etc. Once generated within cells and tissues, ROS can react with a variety of cellular metabolites like fatty acids, proteins or DNA. This review investigates the possibilities for various oxidized metabolites as well as proteomics, genomics and bioimaging biomarkers to serve as early-stage disease biomarkers or biomarkers for drug treatment success. We also assess the value of a step-by-step or cascade biomarker approach as a new paradigm in medical diagnostics. Examples are given for possible analytical methodology and tools as well as statistical methods that could be applied. Such an approach may straighten the road toward new medical diagnostics and treatment regimes, which ultimately could lead to a significantly enhanced medical service for patients suffering from chronic and debilitating or deadly diseases including cancer. Examples from recent research are given to show the progress and possibilities for the proposed model.

Einordnung

Erschienen in:: Current molecular medicine
Vol. 12, H. 6 (2012), S. 716-731
Band:: 12
Heft:: 6
Datum der Veröffentlichung:: 2012
DOI:: 10.2174/156652412800792606
Sprache:: Englisch
Ressourcentyp:: Text
Schlagwörter:: 8 hydroxydeoxyguanosine; accuracy; ACID; ACIDS; ACTIVATION; acute; acute heart infarction; AGE; AGENT; AGENTS; Al; analysis; Animals; antioxidant; antioxidant activity; Antioxidants; Apoptosis; approach; arachidonic acid; article; assessment; ASSOCIATION; automation; BASES; Berlin; bioinformatics; biological marker; Biological Markers; biology; Biomarker; biomarkers; blood level; body weight; BODY-WEIGHT; BRAIN; BREAST-CANCER; cancer; carcinogenesis; catalase; CELL; Cell Death; cholesterol metabolism; CHROMATOGRAPHY-MASS SPECTROMETRY; chronic kidney disease; classification; clinical; Cohort Studies; COMPOUND; compounds; Conjugated linoleic acid; Coronary Disease; creatine kinase MB; creatine kinase MM; Creatinine; criteria; DEATH; development; diagnosis; diagnostic; Diet; DIFFERENCE; DISEASE; disease marker; disease severity; DISEASES; DNA; DNA Damage; docosahexaenoic acid; effect; EFFECTS; Electrophoresis; epidemiology; ethnic group; EXCISION; EXCRETION; fish; FLUID; fluorodeoxyglucose f 18; FORM; gas; Gas Chromatography-Mass Spectrometry; GC-MS; gel; genetic variability; genome; genomics; Genotype; GENOTYPES; german; Germany; glucose regulated protein 78; Glutathione; Groups; growth; growth arrest and DNA damage inducible protein 153; growth factor; GROWTH-FACTOR; guideline; Guidelines; Heart; Human; HUMAN SERUM; HUMAN-SERUM; Humans; IDENTIFICATION; in vivo; IN-VIVO; Inflammation; INSIGHTS; interleukin 10; interleukin 1beta; InterVal; investigation; ions; ischemic heart disease; Isoelectric Focusing; isoprostane derivative; Isoprostanes; ISSUES; Kidney; Laboratories; lesions; LEVEL; Life-long biomarker evaluation; linoleic acid; Lipid Metabolism; lipid peroxidation; LIPID-PEROXIDATION; lipidome; lipidomics; Lung; lung cancer; Macrophages; Male; MAMMALS; MARKERS; Mass Spectrometry; MASS-SPECTROMETRY; MECHANISM; metabolism; Metabolome; metabolomics; metals; method; methods; Mice; model; monitoring; MOUSE; Mutation; MUTATIONS; nanosilver; nanotoxicology; neoplasm; Neoplasms; nonhuman; nucleic acid; OIL; OILS; OXIDATION; Oxidation-Reduction; oxidative DNA damage; oxidative stress; oxygen; Parkinson Disease; Parkinson's disease; PATHOGENESIS; PATHWAY; PATIENT; PEROXIDASE; Phosphorylation; PLASMA; Point Mutation; poisoning; Population; positron emission tomography; Practice Guidelines; Prediction; Prevalence; Probability; product; product safety; products; PROFILE; prostaglandin synthase; protein; protein expression; Proteins; Proteomics; PROTOCOL; QUANTIFICATION; Rat; rats; Reactive Oxygen Species; reference; REGION; regulation; Research; response; RESPONSES; Risk; Risk Assessment; risk factor; risk profile; RISK-ASSESSMENT; Saccharomyces cerevisiae; Safety; sample preparation; secondary; SERA; serum; Signal Transduction; species; SPECIMENS; SPECTROMETRY; sporadic; STATE; STRAIN; STRAINS; Stress; studies; study; superoxide dismutase; Syndrome; SYSTEM; SYSTEMS; TARGET; TARGETS; TECHNOLOGIES; TECHNOLOGY; Testing; tissue; tissues; toxicology; troponin; tumor necrosis factor alpha; two-dimensional electrophoresis; ultraviolet radiation; United States; UNITED-STATES; urine; urine level; USA; validation; variation; VIVO; weight; WOMEN; X box binding protein 1; Xenobiotics
DDC-Sachgruppe der DNB:: 610 Medizin, Gesundheit, Ernährung
Link URL:: http://www.eurekaselect.com/99115/article
Einrichtung:: Bundesinstitut für Risikobewertung, Bundesinstitut für Risikobewertung (bis Juni 2014), Abteilung 7 - Produktsicherheit (bis Juni 2014)
Einrichtung:: Bundesinstitut für Risikobewertung, Bundesinstitut für Risikobewertung (bis Juni 2014), Abteilung 7 - Produktsicherheit (bis Juni 2014), Fachgruppe 72 - Analytik und Expositionsabschätzung
Einrichtung:: Bundesinstitut für Risikobewertung, Bundesinstitut für Risikobewertung (bis Juni 2014), Abteilung 7 - Produktsicherheit (bis Juni 2014), Fachgruppe 73 - Experimentelle Forschung